Discover
TTNP
Titan Pharmaceuticals, Inc.
4.61
undefined x undefined
undefined x undefined
bid
ask
-
0.18
3.76%
04:00 PM
| Ytd | 41.41% | |
| 1y | -11.52% |
4.55
day range
4.80
3.14
52 week range
14.80
| Open | 4.80 | Prev Close | 4.79 | Low | 4.55 | High | 4.80 | Mkt Cap | 2.96M |
| Vol | 2.38M | Avg Vol | 18.01K | EPS | -6.64 | P/E | N/A | Forward P/E | -3.56 |
| Beta | 1.13 | Short Ratio | 0.66 | Inst. Own | 1.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.97 | 200-d Avg | 5.73 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-24 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-15 | 2024-06 | 0 | -2.29 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -1.24 | N/A | N/A |
| 2024-04-02 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-11-14 | 2023-09 | 0 | -0.4 | N/A | N/A |
| 2022-11-14 | 2022-09 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-10-24 | BEN-TZVI AVRAHAM | Director | 66.25K | Stock Award(Grant) |
| 2023-07-25 | CHASEY PETER LOUIS | Director | 50.00K | Stock Award(Grant) |
| 2024-03-17 | CHOONG CHOON HAU | Beneficial Owner of more than 10% of a Class of Security | 3.80M | Conversion of Exercise of derivative security |
| 2023-10-24 | GREENBERG ERIC HOWARD | Director | 66.25K | Stock Award(Grant) |
| 2023-07-25 | LAZAR DAVID ELLIOT | Chief Executive Officer | 100.00K | Stock Award(Grant) |
| 2023-10-24 | MCMURDO MATTHEW CHARLES | Director | 66.25K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Renaissance Technologies, LLC | 11.07K | 35.85K | 1.21% |
| 2024-09-29 | UBS Group AG | 4.77K | 15.46K | 0.52% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 743.00 | 2.41K | 0.08% |
| 2024-09-29 | MCF Advisors LLC | 165.00 | 534.00 | 0.02% |
| 2024-09-29 | Global Wealth Strategies & Associates | 2.00 | 6.00 | 0.00% |
| 2024-09-29 | Osaic Holdings Inc | 10.00 | 32.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 4.10K | 13.29K | 0.45% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 3.15K | 10.19K | 0.34% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 963.00 | 3.12K | 0.11% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 954.00 | 3.09K | 0.10% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2024-01-09 |
| 1 : 30 | 2020-12-01 |
| 1 : 6 | 2019-01-25 |
| 2 : 11 | 2015-09-29 |